COMPOUND PROFILE / COMBINATIONS
Tesamorelin + Ipamorelin.
Research draftThis entry combines tesamorelin and ipamorelin.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Identity and evidence review notes
Component references are background only. No directly matched controlled combination result was established in this pass.
Overview
This entry combines tesamorelin and ipamorelin.
Mechanism
Both can affect the GH axis through different upstream receptors.
Human research
Tesamorelin's approved disease-specific evidence does not establish the combination's benefit.
Preclinical & other research
Component models are background, not tests of a commercial stack.
Safety & unknowns
GH, IGF-1 and glucose-related effects may overlap; combined safety is not established.
Regulatory status
Egrifta's authorisation does not extend to this mixture.
Reported use & evidence
The supplied Tesamorelin + Ipamorelin profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.